Janssen receives new approval for Darzalex in Canada
Canadian authorities have approved the use of Darzalex, which is Genmab-developed, for treating the rare disease amyloidosis.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Janssen is still working hard to promote its big seller Darzalex, and this is now paying off in Canada.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst: Genmab share price may double
For subscribers
